{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:35:57Z","timestamp":1789734957646,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.clinthera.2008.09.015","type":"journal-article","created":{"date-parts":[[2008,10,6]],"date-time":"2008-10-06T08:24:48Z","timestamp":1223281488000},"page":"1590-1617","source":"Crossref","is-referenced-by-count":26,"title":["Ixabepilone: A novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Michael","family":"Steinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 18","key":"10.1016\/j.clinthera.2008.09.015_bib1","first-page":"47S","article-title":"Anticancer drug discovery and development throughout the world","volume":"20","author":"Schwartsmann","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","article-title":"Epothilones: Mechanism of action and biologic activity","volume":"22","author":"Goodin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib3","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib4","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1200\/JCO.2006.09.7535","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roch\u00e9","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib5","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1200\/JCO.2005.02.4448","article-title":"Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A South-west Oncology Group Trial S0111","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib6","series-title":"Ixempra (ixabepilone) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2008.09.015_bib7","doi-asserted-by":"crossref","first-page":"39431","DOI":"10.1074\/jbc.M401530200","article-title":"Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2008.09.015_bib8","first-page":"466","article-title":"Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells","volume":"62","author":"Yamaguchi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.vph.2007.01.006","article-title":"Cell suicide and caspases","volume":"46","author":"Rupinder","year":"2007","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-8258(03)00006-4","article-title":"Molecular determinants of epothilone B derivative (BMS 247550) and Apo2L\/TRAIL-induced apoptosis of human ovarian cancer cells","volume":"89","author":"Griffin","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib11","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1093\/emboj\/20.23.6627","article-title":"Apoptosis-associated release of Smac\/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2","volume":"20","author":"Adrain","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.clinthera.2008.09.015_bib12","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood.V99.9.3419","article-title":"Ectopic overexpression of second mitochondria-derived activator of caspases (Smac\/DIABLO) or cotreatment with N-terminus of Smac\/DIABLO peptide potentiates epothilone B derivative-(BMS-247550) and Apo-2L\/TRAIL-induced apoptosis","volume":"99","author":"Guo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2008.09.015_bib13","first-page":"1429","article-title":"BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib14","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.2003.03.063","article-title":"Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days","volume":"21","author":"Abraham","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","article-title":"Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors","volume":"10","author":"Mani","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib16","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/1078-0432.CCR-05-0127","article-title":"Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design","volume":"11","author":"Gadgeel","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2006.08.7304","article-title":"Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas","volume":"25","author":"Aghajanian","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10637-007-9041-z","article-title":"Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry","volume":"25","author":"Beumer","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/annonc\/mdl315","article-title":"Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone","volume":"18","author":"Mani","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib20","first-page":"80s","article-title":"A phase I pharmacokinetic (PK) study of the epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment","volume":"24","author":"Takimoto","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib21","first-page":"80s","article-title":"Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone","volume":"24","author":"Goel","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib22","first-page":"2035","article-title":"Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study","volume":"8","author":"McDaid","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0167-8140(03)00200-7","article-title":"Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells","volume":"68","author":"Kim","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib24","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib25","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxaneresistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib26","first-page":"151s","article-title":"Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies","volume":"22","author":"Anderson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib27","first-page":"56a","article-title":"Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-naive or taxane-refractory metastatic breast cancer","volume":"21","author":"Roch\u00e9","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib28","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2005.10.024","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer","volume":"23","author":"Low","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10637-006-9006-7","article-title":"Phase II trial of ixabepilone, an epothilone B analog, given for three days every three weeks, in metastatic breast cancer","volume":"25","author":"Denduluri","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib30","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2006.10.0784","article-title":"Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes","volume":"25","author":"Denduluri","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib31","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib32","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2008.16.5019","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"26","author":"Thomas","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib33","first-page":"114s","article-title":"Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229","volume":"25","author":"Chuang","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib34","first-page":"103s","article-title":"Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients","volume":"25","author":"Wu","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib35","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1200\/JCO.2005.09.042","article-title":"Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer","volume":"23","author":"Galsky","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/annonc\/mdg415","article-title":"Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration","volume":"14","author":"Smaletz","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2008.09.015_bib38","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2006.09.7097","article-title":"Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small cell lung cancer whose tumors have failed first-line platinum-based chemotherapy","volume":"25","author":"Vansteenkiste","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10637-006-7304-8","article-title":"A multi-center phase II study of BMS-247550 (ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane","volume":"24","author":"Ajani","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib40","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdh236","article-title":"A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer","volume":"15","author":"Eng","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10637-006-8440-x","article-title":"A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study","volume":"24","author":"Whitehead","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/cncr.22839","article-title":"Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group","volume":"110","author":"Dreicer","year":"2007","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib43","first-page":"394a","article-title":"A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent, in renal cell cancer","volume":"22","author":"Zhuang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10637-007-9059-2","article-title":"Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors","volume":"25","author":"Feldman","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib45","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.00.372","article-title":"Evaluation of epothilone B analog in advanced soft tissue sarcoma: A phase II study of the Phase II consortium","volume":"23","author":"Okuno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdm591","article-title":"A randomized phase II study of ixabepilone (BMS-247550) given daily \u00d7 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study","volume":"19","author":"Burtness","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib47","first-page":"118s","article-title":"A phase I\/II trial of BMS-247550 for patients with recurrent high-grade gliomas","volume":"22","author":"Peereboom","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib48","first-page":"129s","article-title":"NABTT 2111: A phase I trial of BMS-247550 for patients with recurrent high-grade gliomas","volume":"23","author":"Peereboom","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib49","first-page":"591s","article-title":"A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib50","first-page":"577s","article-title":"Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib51","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.20977","article-title":"A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days","volume":"103","author":"Zhuang","year":"2005","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2008.09.015_bib52","first-page":"139s","article-title":"Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies","volume":"22","author":"Faivre","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.09.015_bib53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10637-007-9035-x","article-title":"A Phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors","volume":"25","author":"Hensley","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.09.015_bib54","first-page":"2279","article-title":"Dermatological toxicity of ixabepilone","volume":"26","author":"Conlin","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib55","first-page":"3531","article-title":"Nail disorders in a woman treated with ixabepilone for metastatic breast cancer","volume":"25","author":"Alimonti","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2008.09.015_bib56","series-title":"Red Book Update-March 2008","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808003081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T08:25:20Z","timestamp":1545726320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808003081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0149291808003081"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.09.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}